In the high-stakes world of biotechnology, a single word can be the difference between a breakthrough and a budgetary dead end. Moderna, the Massachusetts-based biotech firm that rose to global prominence with its COVID-19 shot, is currently navigating a complex linguistic shift. The company is increasingly distancing its latest cancer research from the word “vaccine,” opting instead for the more clinical term “individualized neoantigen therapy.”
This shift toward individualized neoantigen therapy is not merely a matter of scientific precision. It is a strategic pivot occurring against a backdrop of shifting federal priorities and rising vaccine skepticism within the U.S. Government. As mRNA technology faces latest political headwinds, the rebranding serves as a shield for innovation that could potentially transform oncology.
The tension is most evident in the company’s partnership with Merck. Although the technology functions mechanistically like a vaccine—training the immune system to recognize and destroy specific targets—the branding has shifted. By framing the treatment as a “therapy,” Moderna and Merck are positioning the product as a medical intervention for patients who already have a disease, rather than a preventive measure for the general public.
This linguistic maneuver comes at a critical time for Moderna. The company has faced significant setbacks in its infectious disease portfolio, including the unwinding of support for projects like a bird flu vaccine. With federal contracts under scrutiny and regulators becoming less friendly toward mRNA applications, the “therapy” label may be the only way to ensure that life-saving cancer research continues without being caught in the crossfire of a broader political war on vaccines.
The Science of Individualized Neoantigen Therapy
To understand why the “vaccine” label is so contentious, one must first understand how the technology works. Individualized neoantigen therapy (INT) is a personalized approach to treating cancer. Rather than using a one-size-fits-all shot, Moderna sequences a specific patient’s cancer cells to identify “neoantigens”—peculiar molecules on the surface of the tumor that are not found on healthy cells.
Once these markers are identified, Moderna packages the genetic code for those specific molecules into an mRNA shot. When administered, the patient’s immune system is essentially given a “wanted poster” for the cancer cells. The immune system is then ordered to seek out and kill any cells displaying those specific surface markers.
Mechanistically, this process is very similar to the mRNA COVID-19 vaccines. The primary difference is the target: while the COVID-19 vaccine immunizes the body against a virus, INT immunizes the body against a patient’s own specific cancer. The results have been promising; recently, Moderna and Merck demonstrated that these shots halved the chance that patients with the deadliest form of skin cancer would die from a recurrence after surgery.
A Strategic Pivot Amidst Political Turbulence
The decision to stop using the word “vaccine” in formal communications and regulatory filings began around 2023. Moderna’s CEO stated at the time that the renaming was intended to “better describe the goal of the program.” However, industry observers and medical professionals suggest a deeper motive: distancing the research from “vaccine fearmongering” fueled by high-ranking U.S. Officials.
The impact of this political climate is tangible. Robert F. Kennedy Jr., head of the Department of Health and Human Services, has reportedly targeted mRNA projects, leading to the unwinding of support for numerous initiatives. This includes a reported $776 million award to Moderna for a bird flu vaccine. By January, the company warned that it might have to halt late-stage programs for vaccines against infections entirely.
Kyle Holen, head of Moderna’s cancer program, acknowledged the difficulty of the current climate during BIO 2025, a biotech event in Boston, noting that while “vaccines are maybe a dirty word nowadays,” the company remains committed to harnessing the immune system to fight cancers.
Moderna is not alone in this trend. BioNTech, the European maker of mRNA vaccines, has similarly shifted its language, moving from the term “neoantigen vaccine” in 2021 to “mRNA cancer immunotherapies” in its most recent reports.
The Ethical Debate: Transparency vs. Survival
Not all medical professionals are comfortable with this rebranding. Some argue that the shift in terminology creates a transparency gap that could affect patient care. Ryan Sullivan, a physician at Massachusetts General Hospital who has enrolled patients in Moderna’s trials, has expressed concern that trial volunteers may not be properly informed. Sullivan noted a worry that some patients might decline a potentially life-saving treatment simply because they believe it is a “vaccine,” or conversely, that the nature of the treatment is being obscured.
For many physicians, calling the treatment a vaccine is a matter of scientific integrity. They argue that it is important to “call it what it is” to defend the broader science of immunization, which remains one of the most successful public health interventions in history.
However, other experts believe the trade-off is necessary. Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre in Toronto, suggests that a name change is acceptable if it allows the research to actually continue. The priority is the survival of the patient and the advancement of the cure, regardless of the terminology used to describe the delivery mechanism.
The Erasure of the ‘V-Word’
The commitment to this new branding is becoming absolute. In a research paper published in February, the main text of Moderna’s latest results avoided the word “vaccine” entirely. The term appeared only in the footnotes, tucked away in the titles of older patents and previous papers.
This erasure suggests that the strategy of the current administration—to produce mRNA vaccines a focal point of public worry and devalue them for biotech companies—is having a chilling effect on the industry. By scrubbing the “V-word” from their primary texts, Moderna is attempting to bypass the political friction associated with mRNA vaccines to ensure their cancer therapy reaches the clinic.
While the government has remained largely silent on the “individualized neoantigen therapy,” the tension remains. The company is essentially betting that by changing the name, they can save the science.
Key Takeaways: Vaccine vs. Therapy
- The Technology: Moderna’s cancer treatment uses mRNA to teach the immune system to attack specific neoantigens on a patient’s tumor.
- The Rebrand: Since 2023, Moderna has shifted from calling this a “cancer vaccine” to “individualized neoantigen therapy” (INT).
- The Motivation: The shift is largely seen as a way to avoid political backlash and vaccine skepticism currently prevalent in the U.S. Federal government.
- The Impact: Clinical results present the therapy can halve the risk of death from recurrence in certain deadly skin cancers.
- The Controversy: Some doctors worry the name change compromises informed consent, while others argue it is necessary for the research to survive.
As Moderna continues to navigate this “vocabulary paradox,” the focus remains on the upcoming regulatory filings and the progression of clinical trials for its INT program. The biotech world will be watching closely to see if this linguistic shield is enough to protect the next generation of mRNA medicine from political instability.
Do you believe that rebranding scientific breakthroughs to avoid political controversy is a necessary evil or a compromise of medical transparency? Share your thoughts in the comments below.
Keep reading